# BPX-603

Source: https://onco.cc/drugs/bpx-603/  
OnCo record `bpx-603` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

BPX-603 is an autologous dual-switch CAR-T cell therapy from Bellicum Pharmaceuticals that reached phase 1 for HER2-positive solid tumours, HER2-positive gastric cancer and HER2-positive breast cancer; development has stopped.

## Summary

BPX-603 is an autologous dual-switch CAR-T cell therapy (GoCAR platform) from Bellicum Pharmaceuticals. An autologous dual-switch GoCAR-T product containing both the iMC activation and CaspaCIDe safety switches, designed to target solid tumours that express HER2. Its furthest stage is phase 1, for HER2-positive solid tumours, HER2-positive gastric cancer and HER2-positive breast cancer. ClinicalTrials.gov registers it in one study linked below. Bellicum announced on 14 March 2023 that it would discontinue the phase 1/2 trials of BPX-601 and BPX-603; registry status of NCT04650451 is SUSPENDED. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest; discontinued
- Code: BPX-603
- Modality: Autologous dual-switch CAR-T cell therapy (GoCAR platform)
- Mechanism: An autologous dual-switch GoCAR-T product containing both the iMC activation and CaspaCIDe safety switches, designed to target solid tumours that express HER2.

## Sources

- Bellicum Pharmaceuticals: sec.gov: https://www.sec.gov/Archives/edgar/data/1358403/000162828023010145/blcm-20221231.htm
- Bellicum Pharmaceuticals: sec.gov: https://www.sec.gov/Archives/edgar/data/1358403/000153949723002188/exh99-1.htm
- ClinicalTrials.gov: trials of BPX-603: https://clinicaltrials.gov/search?intr=BPX-603

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/), [HER2-positive gastric cancer](https://onco.cc/cancers/gastric-her2-positive/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- targets: [HER2](https://onco.cc/targets/her2/)
- companies: [Bellicum Pharmaceuticals](https://onco.cc/companies/bellicum/)
- trials: [Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors](https://onco.cc/trials/nct04650451/)

---
JSON: https://onco.cc/api/v1/entities/bpx-603.json